Caris Molecular Intelligence Service examines the genetic and molecular makeup that is unique to each patient’s tumour. By comparing the tumour's information with data from clinical studies from thousands of the world's leading cancer researchers, Caris can help the physician determine which treatments are likely to be most effective and which treatments are likely to be ineffective for each patient. Caris Molecular Intelligence can be used to inform treatment selection when treating aggressive or rare tumors, or refractory disease.
The Prosigna Breast Cancer Prognostic Gene Signature Assay is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care, either as:
Breakthrough genomic cancer testing from a single blood draw Guardant Health has helped thousands of oncologists learn accurate and actionable information about tens of thousands of patients, while avoiding the costs and risks of tissue biopsies. Guardant Health genomic test helps match advanced-cancer patients to approved targeted therapies as well as drugs in clinical trials.
Immunoscore® is an in vitro diagnostic test predicting the risk of relapse in early stage colon cancer patients, by measuring the host immune response at the tumor site.
It is a risk-assessment tool that provides independent and superior prognostic value than the usual tumor risk parameters, and should be used as an adjunct to the TNM classification (Pagès F et al. The Lancet 2018, Sinicrope F et al. J Clin Oncol 2018). Immunoscore® can thus improve individual patient treatment strategies, particularly the modulation of adjuvant chemotherapy in stage II and stage III.